explore -WSS

explore

author：comprehensive 2025-09-03 03:44:19 - browse：32745

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Novo: Oral version of Ozempic leads to 15% weight loss

entertainment

WSS

Eli Lilly, Pfizer, and others want in on the online prescription market

Novo: Oral version of Ozempic leads to 15% weight loss

Francis Collins on trust in science and how Covid communications failed

Mom launches Girl Scout troop for LGBTQ youth in Texas

Copay coupons to count toward deductibles, after Biden court move

eGenesis tests gene

explore

explore

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Timeline: Key moments in fight for gay rights

Peter Hotez and the public health issue of online harassment

Novo: Oral version of Ozempic leads to 15% weight loss

23andMe had bad news about my health. I wish a person had delivered it

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Bright Health sells Medicare Advantage business to Molina

Inside the rise of 'mukbang' eating videos

Bright Health sells Medicare Advantage business to Molina

Can medical device makers keep up in the race to treat obesity?

focus

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Eli Lilly, Pfizer, and others want in on the online prescription market

Novo pauses ads for weight loss drug Wegovy amid demand

Research misconduct: Proposed new rules face resistance

Parkinson’s finding may lead to tests and, someday, treatments

A public health expert passes on football's full body collisions for youths

entertainment

explore

hotspot

hotspot